The NHS North East Treatment Advisory Group (NETAG) has issued a recommendation and associated appraisal report on the use of botulinum toxin type A (Botox®) for the treatment of chronic migraine. The Group did not recommend its use as it was concerned about the clinical efficacy of treatment and important uncertainties remained regarding interpretation of cost effectiveness.